GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vera Therapeutics Inc (NAS:VERA) » Definitions » Preferred Stock

Vera Therapeutics (Vera Therapeutics) Preferred Stock : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Vera Therapeutics Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Vera Therapeutics's preferred stock for the quarter that ended in Mar. 2024 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Vera Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 was $1,995.52 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Vera Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 was $6.49.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Vera Therapeutics's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $-0.56.


Vera Therapeutics Preferred Stock Historical Data

The historical data trend for Vera Therapeutics's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vera Therapeutics Preferred Stock Chart

Vera Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Preferred Stock
- - - - -

Vera Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Vera Therapeutics Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Vera Therapeutics  (NAS:VERA) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Vera Therapeutics's Enterprise Value for the quarter that ended in Mar. 2024 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Vera Therapeutics's Book Value per Share for the quarter that ended in Mar. 2024 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Vera Therapeutics's Earnings per Share (Diluted) (EPS) for the three months ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vera Therapeutics Preferred Stock Related Terms

Thank you for viewing the detailed overview of Vera Therapeutics's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Vera Therapeutics (Vera Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
8000 Marina Boulevard, Suite 120, Brisbane, CA, USA, 94005
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Executives
Commodore Capital Lp 10 percent owner 444 MADISON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Marshall Fordyce director, officer: President and CEO C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Celia Lin officer: Chief Medical Officer C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Joanne Curley officer: Chief Development Officer C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE, SOUTH SAN FRANCISCO CA 94080
Sean Grant officer: Chief Financial Officer C/O VERA THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 120, BRISBANE CA 94005
Beth C Seidenberg director
Sofinnova Management X-a, L.l.c. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Sofinnova Venture Partners X, L.p. 10 percent owner 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Longitude Capital Partners Iv, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Partners, Llc 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Longitude Prime Fund, L.p. 10 percent owner 2740 SAND HILL ROAD, 2ND FLOOR, MENLO PARK CA 94025
Patrick G Enright director, 10 percent owner CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Llp Abingworth 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Abingworth Bioventures 8 Lp 10 percent owner 38 JERMYN STREET, LONDON X0 SW1Y 6DN
Carlyle Group Inc. 10 percent owner C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004

Vera Therapeutics (Vera Therapeutics) Headlines

From GuruFocus

FMR LLC Adjusts Stake in Vera Therapeutics Inc

By GuruFocus Research 11-14-2023

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

By Stock market mentor Stock market mentor 02-02-2023